SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Tiensuu Janson Eva)
 

Sökning: WFRF:(Tiensuu Janson Eva) > (2020-2024) > Treatment efficacy ...

Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort

Papantoniou, Dimitrios (författare)
Uppsala universitet,Onkologisk endokrinologi,Ryhov Cty Hosp, Dept Oncol, Jönköping, Sweden.,Uppsala Univ, Sweden; Ryhov Cty Hosp, Sweden
Grönberg, Malin, 1980- (författare)
Uppsala universitet,Onkologisk endokrinologi,Uppsala Univ, Sweden
Thiis-Evensen, Espen (författare)
Oslo Univ Hosp, Rikshosp, Dept Organ Transplant, Oslo, Norway.
visa fler...
Sorbye, Halfdan (författare)
Haukeland Hosp, Dept Oncol, Bergen, Norway.;Univ Bergen, Dept Clin Med, Bergen, Norway.
Landerholm, Kalle (författare)
Linköpings universitet,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Ryhov Cty Hosp, Sweden
Welin, Staffan (författare)
Uppsala universitet,Onkologisk endokrinologi,Uppsala Univ, Sweden
Tiensuu Janson, Eva (författare)
Uppsala universitet,Onkologisk endokrinologi,Uppsala Univ, Sweden
visa färre...
 (creator_code:org_t)
Bioscientifica, 2023
2023
Engelska.
Ingår i: Endocrine-Related Cancer. - : Bioscientifica. - 1351-0088 .- 1479-6821. ; 30:3
Relaterad länk:
https://doi.org/10.1...
visa fler...
https://uu.diva-port... (primary) (Raw object)
https://liu.diva-por... (primary) (Raw object)
https://urn.kb.se/re...
https://doi.org/10.1...
https://urn.kb.se/re...
visa färre...
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Small intestinal neuroendocrine tumours (Si-NET) are often studied as a uniform group. Proliferation index Ki-67 influences prognosis and determines tumour grade. We hypothesized that Si-NET grade 2 (G2) tumours, which have a higher Ki-67 than G1 tumours, might benefit less from established treatments for metastatic disease. We conducted a retrospective cohort study of 212 patients with metastatic Si-NET G2 treated in two Swedish hospitals during 20 years (2000-2019). Median cancer-specific survival on first-line somatostatin analogues (SSA) was 77 months. Median progression-free survival (PFS) was 12.4 months when SSA was given as monotherapy and 19 months for all patients receiving first-line SSA. PFS after SSA dose escalation was 6 months in patients with radiological progression. Treatment efficacies of SSA and peptide receptor radionuclide treatment (PRRT) were studied separately in patients with Ki-67 of 3-5%, 5-10% and 10-20%. For SSA, PFS was significantly shorter at higher Ki-67 levels (31, 18 and 10 months, respectively), while there was only a minor difference in PFS for PRRT (29, 25 and 25 months). Median PFS for sequential treatment with interferon-alpha (IFN alpha), everolimus and chemotherapy was 6, 5 and 9 months. IFN alpha seemed to be effective in tumours with low somatostatin-receptor expression. In conclusion, established treatments appeared effective in Si-NET G2, despite their higher proliferation index compared to G1 tumours. However, efficacy of SSA but not PRRT was reduced at higher Ki-67 levels. SSA dose escalation provided limited disease stabilization.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Gastroenterologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)

Nyckelord

small intestinal neuroendocrine tumours
Si-NET
grade 2
somatostatin analogues
interferon
PRRT
peptide receptor radionuclide treatment
Ki-67
somatostatin receptor negative

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy